
Abstract serial number: 460 Poster Number: P3-P031





Growth hormone treatment of 2 patients with X-linked hypophosphatemic rickets caused by PHEX mutation: effects on linear growth



Max GH

Aleksandra Rojek¹, Monika Obara-Moszynska², <u>Marek Niedziela^{1,2}</u>

1 Poznan University of Medical Sciences, Department of Pediatric Endocrinology and Rheumatology, Molecular Endocrinology Laboratory, Poznan, Poland, e-mail: <u>aleksandra.rojek@gmail.com</u> 2 Poznan University of Medical Sciences, Department of Pediatric Endocrinology and Rheumatology, Poznan, Poland,

e-mail: mmoszynska@ump.edu.pl; mniedzie@ump.edu.pl


OBJECTIVES

Hypophosphatemic rickets (HR) is a group of rare disorders caused by an excessive renal phosphate wasting. X-linked HR (XLHR) is caused by mutation in PHEX (phosphateregulating endopeptidase) gene and is characterized mainly by bone deformities, disproportionately short stature, dental anomalies and hypophosphatemia with coexisting low renal phosphate reabsorption. Early treatment with vitamin D and phosphate improves the patient's growth. Recombinant human growth hormone (rhGH) may also improve growth in XLHR through a direct effect on growth cartilage, and by increasing renal phosphate reabsorption and serum phosphate levels.

CASE PRESENTATION


2 patients, 8.25 years old girl and 6.75 years old boy were diagnosed with HR at the age of 2.25 years and then treated with alfacalcidol (73 and 69 ng/kg/d) and phosphorus (175 and 30 mg/kg/d). Due to the diagnosis of growth hormone deficiency rhGH therapy was initiated at the age of 6.75 years and 4.75 years, respectively (current doses of rhGH are 0,029 and 0.028 mg/kg/d).


X-Linked Dominant Hypophosphatemic Rickets



Patient	Sex	Age	Age at diagnosis	diagnosis/1st stay at department	Current Ht SDS	Clinical symptoms/ family interview		Ear problems	Dental problems		Other clinica features	al After stimulation Normal range > 10 ng/ml	Current treatment
1	F	8 3/12	2 3/12	-3,7	-3.4	bowing of l limbs, sh stature AFFECTED F/	ort e	no	no		no	5.2	rhGH: 0.029 mg/kg/d Phosphorus: 175 mg/kg/d Alfacalcidol 73 ng/kg/d
2	М	6 9/12	2 3/12	-2.3	-2.1	bowing of lowe limbs, short stature, fronta bossing, wideni of distal parts o forearms		no	gingivitis		no	7.1	rhGH: 0.028 mg/kg/d Phosphorus: 30 mg/kg/d Alfacalcidol 69 ng/kg/d
PATIEN	T (S-Ca (N 2,2-2 mmol/		-7 (N 93-)	309 (1	S-PTH N 15-68,3 pg/ml)	25(0 (N 59,1 30	S- OH)D3 9,4- L; opt. D-50 (/ml)	U-Ca (N <4 mg/kg/d)		U-P 116-20 g/kg/d)	TRP1 % (N>80%) At the diagnosis	TRP2 % (N>80%) During therapy
1		2,44	↓3, :	13 个 52	22	个354		21	39,6		0,4	个 23,28	84
2		2,59	↓2 ,4	46 个 73	30	个335	3	0,7	26,4		0,2	<u> </u>	84
S – seru	m U	I – urin	e ALP-	alkaline pho	osphata	ase TRP -	Tubu	ılar reak	osorption o	of pł	nosphate		

The aim of the study was to investigate the clinical phenotype and molecular background of HR in family in which XLHR was a suspected.





METHODS AND RESULTS

DNA was isolated from fresh blood and all exons of *PHEX* gene were amplified using PCR and directly sequenced.

The dominant clinical signs in both patients were bowing of legs and short stature. HtSDS at the time of diagnosis was -3.7 and -2.3, respectively. Current htSDS is -3.4 and -2.1, respectively and the height gain during rhGH therapy was +0.3 and +1.04 SD. In the patient 1, we found a known c.C716>T, p.T239M heterozygous polymorphism (rs7955866) in FGF23 gene which was absent in the patient's affected father. We also found a novel heterozygous mutation c.326_327insCA, N110lfs*7 in PHEX gene which was also present in the patient's father. FGF23 in the patient 2 was intact, but we found a known hemizygous mutation c.1801_2250del in PHEX gene covering exon 17 to exon 22.

CONCLUSIONS

References

- Early clinical and molecular diagnosis of HR, and early implementation of vitamin D and phosphorus is crucial to prevent severe bone deformities and to improve final height.
- rhGH therapy in patients with XHLR may be very effective in those with coexisting growth hormone deficiency.
- Genetic counseling in families with HR patients should be proposed.

1. M. Sloman, K. Thomas, C. Tysoe, S. Ellard Department of Molecular Genetics. A Diagnostic Testing Service for Hypophosphatemic Rickets 2. Angham Al-Mutair, Rajaa A., 2017, Types of rickets. Annals of Orthopedics & Rheumatology 5(2): 1085 3. Patel L., Clayton PE, Brain C., et al. 1996. Acute biochemical effects of

growth hormone treatment compared with conventional treatment in familial hypophosphatemic rickets. Clin Endocrinol 44: 687-696

There is no conflict of interest.

eeting ATHENS (

This work was supported by funds of Department of Pediatric Endocrinology and Rheumatology of Poznan University of Medical Sciences (Nr 502-01-01104118-06037 to Marek Niedziela) and by a Research Grant of the Department of Pediatric Endocrinology and Rheumatology of Poznan University of Medical Sciences (Nr 502-1401104118-09627 to Aleksandra Rojek)



Bone, growth plate and mineral metabolism

Aleksandra Rojek

Poster presented at:



